Evidence map›Paper›PMID 36845830›Full record

ArticleFrontiers in antibiotics2023

Resistance-resistant antibacterial treatment strategies.

Jonathan I Batchelder, Patricia J Hare, Wendy W K Mok

Registry-linked trialAbstract read
In one paragraph

Article in Frontiers in antibiotics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06811727 (CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients With Klebsiella Pneumoniae OXA-48 or Pseudomonas Aeruginosa Infections), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06811727 phase4not yet recruitingnot on this mapstarted 2025, after this paper: background citation

CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients With Klebsiella Pneumoniae OXA-48 or Pseudomonas Aeruginosa Infections: A Single-centre Randomized Open-label Trial (ZAVICONT)

TypeinterventionalSponsorIvan Šitum, MDRan2025 to 2027Enrolled140ConditionsSevere InfectionArmsContinuos ceftazidime/avibactam infusion, Intermitent dosing as per SMPC
3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Virulence · 2026
    Review
  2. Article
  3. ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  4. Review
  5. Article
  6. Antimicrobial Activity ofAntibiotics (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jonathan I BatchelderDepartment of Molecular Biology and Biophysics, UConn Health, Farmington, CT, United States.
Patricia J HareDepartment of Molecular Biology and Biophysics, UConn Health, Farmington, CT, United States.
Wendy W K MokDepartment of Molecular Biology and Biophysics, UConn Health, Farmington, CT, United States.

Funding

Skeletal, Craniofacial and Oral Biology Training GrantT90DE021989 · NIDCR · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI MINA, MINA · 2011 to 2022
$4.5M
Mapping polymicrobial interactions that modulate antibiotic persistenceDP2GM146456 · NIGMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI MOK, WENDY W.K. · 2021 to 2021
$1.5M
NIDCR NIH HHS T90 DE021989NIGMS NIH HHS DP2 GM146456
6 · The paper itself

Abstract

Antibiotic resistance is a major danger to public health that threatens to claim the lives of millions of people per year within the next few decades. Years of necessary administration and excessive application of antibiotics have selected for strains that are resistant to many of our currently available treatments. Due to the high costs and difficulty of developing new antibiotics, the emergence of resistant bacteria is outpacing the introduction of new drugs to fight them. To overcome this problem, many researchers are focusing on developing antibacterial therapeutic strategies that are "resistance-resistant"-regimens that slow or stall resistance development in the targeted pathogens. In this mini review, we outline major examples of novel resistance-resistant therapeutic strategies. We discuss the use of compounds that reduce mutagenesis and thereby decrease the likelihood of resistance emergence. Then, we examine the effectiveness of antibiotic cycling and evolutionary steering, in which a bacterial population is forced by one antibiotic toward susceptibility to another antibiotic. We also consider combination therapies that aim to sabotage defensive mechanisms and eliminate potentially resistant pathogens by combining two antibiotics or combining an antibiotic with other therapeutics, such as antibodies or phages. Finally, we highlight promising future directions in this field, including the potential of applying machine learning and personalized medicine to fight antibiotic resistance emergence and out-maneuver adaptive pathogens.

Indexed as

antibiotic resistancecombination therapiesevolutionary steeringmutationstress response

Identifiers

PMID36845830
PMCPMC9954795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.